Emerging therapies in severe sepsis

Thorax

Volumn 57, Issue SUPPL. 2, 2002, Pages

  Finney, S J ^a   Evans, T W ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 11A; BLOOD CLOTTING FACTOR 8A; D DIMER; DROTRECOGIN; HEPARIN; INSULIN; INTERLEUKIN 6; PROTEIN C;

ARTIFICIAL VENTILATION; BLEEDING; BLOOD CLOTTING; CLINICAL PRACTICE; CLINICAL TRIAL; CRITICAL ILLNESS; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HEMODYNAMICS; HUMAN; HYPERGLYCEMIA; INSULIN TREATMENT; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEPSIS; SEPTIC SHOCK;

ANTICOAGULANTS; ANTITHROMBIN III; FLUID THERAPY; HEMODYNAMIC PROCESSES; HUMANS; INSULIN; INTENSIVE CARE; PROTEIN C; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0036795040     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Sands KE, Bates DW, Lanken PN, et al. Epidemiology of sepsis syndrome in 8 academic medical centers. Academic Medical Center Consortium Sepsis Project Working Group. JAMA 1997;278:234-40.
2. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10.
3. Rangel-Frausto MS, Pittet D, Costigan M, et al. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995;273:117-23.
4. Cohen J, Guyatt G, Bernard GR, et al. New strategies for clinical trials in patients with sepsis and septic shock. Crit Care Med 2001;29:880-6.
5. Bernard GR, Vincent JL, Laterre PF, et a. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
6. Warren BL, Eid A, Singer P, et al. High dose antithrombin III in severe sepsis. A randomized controlled trial. JAMA 2001;286:1869-78.
7. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. New Engl J Med 2001;345:1359-67.
8. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. New Engl J Med 2001;345:1368-77.
9. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-74.
10. Van der Poll T, Buller HR, Ten Care H, et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990;322:1622-7.
11. Van der Poll T, Levi M, Hack CE, et al. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 1994;179:1253-9.
12. Shimura M, Wada H, Wakita Y, et al. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Am J Hematol 1997;55:169-74.
13. Osterud B, Flaegstad T. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis. Thromb Haemost 1983;49:5-7.
14. Taylor FB Jr, Chang A, Ruf W, et al. Lethal E coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991;33:127-34.
15. Levi M, Ten Cate H, Bauer KA, et al. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994;93:114-20.
16. Fourrier F, Lestavel P, Chopin C, et al. Meningococcemia and purpura fulminans in adults: acute deficiencies of proteins C and S and early treatment with antithrombin III concentrates. Intensive Care Med 1990;16:121-4.
17. Kidokoro A, Iba T, Fukunaga M, et al. Alterations in coagulation and fibrinolysis during sepsis. Shock 1996;5:223-8.
18. Mesters RM, Florke N, Ostermann H, et al. Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb Haemost 1996;75:902-7.
19. Esmon CT, Fukudome K, Mather T, et al. Inflammation, sepsis, and coagulation. Haematologica 1999;84:254-9.
20. Creasey AA, Reinhart K. Tissue factor pathway inhibitor activity in severe sepsis. Crit Care Med 2001;29:S126-9.
21. Creasey AA, Chang AC, Feigen L, et al. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993;91:2850-6.
22. Opal SM. Therapeutic rationale for antithrombin III in sepsis. Crit Care Med 2000;28:S34-7.
23. Horie S, Ishii H, Kazama M. Heparin-like glycosaminoglycan is a receptor for antithrombin III- dependent but not for thrombin-dependent prostacyclin production in human endothelial cells. Thromb Res 1990;59:895-904.
24. Mesters RM, Helterbrand J, Utterback BG, et al. Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Crit Care Med 2000;28:2209-16.
25. Lorente JA, Garcia-Frade LJ, Landin L, et al. Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 1993;103:1536-42.
26. Fisher CJ, Jr., Yan SB. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit Care Med 2000;28:S49-56.
27. Taylor F, Chang A, Ferrell G, et al. C4b-binding protein exacerbates the host response to Escherichia coli. Blood 1991;78:357-63.
28. Faust SN, Levin M, Harrison OB, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001;345:408-16.
29. Taylor FB Jr, Wada H, Kinasewitz G. Description of compensated and uncompensated disseminated intravascular coagulation (DIC) responses (non-overt and overt DIC) in baboon models of intravenous and intraperitoneal Escherichia coli sepsis and in the human model of endotoxemia: toward a better definition of DIG. Crit Care Med 2000;28:S12-9.
30. Bernard GR, Ely EW, Wright TJ, et al. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 2001;29:2051-9.
31. Taylor FB, Jr., Chang A, Esmon CT, et al. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987;79:918-25.
32. Yan SB, Dhainaut J-F. Activated protein C versus protein C in severe sepsis. Crit Care Med 2001;29:S69-S74.
33. Grinnell BW, Joyce D. Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis. Crit Care Med 2001;29:S53-60; discussion S60-1.
34. Shoemaker WC, Chang P, Czer L, et al. Cardiorespiratory monitoring in postoperative patients: I. Prediction of outcome and severity of illness. Crit Care Med 1979;7:237-42.
35. Bland R, Shoemaker WC, Shabot MM. Physiologic monitoring goals for the critically ill patient. Surg Gynecol Obstet 1978;147:833-41.
36. Boyd O, Hayes M. The oxygen trail: the goal. Br Med Bull 1999;55:125-39.
37. Reinhart K, Rudolph T, Bredle DL, et al. Comparison of central-venous to mixed-venous oxygen saturation during changes in oxygen supply/demand. Chest 1989;95:1216-21.
38. Hayes MA, Timmins DC, Yau EW, et al. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994;330:1717-22.
39. Gattinoni L, Brazzi L, Pelosi P, et al. A trial of goal orientated hemodynamic therapy in critically ill patients. N Engl J Med 1995;333:1025-32.
40. Lee J, Wright F, Barber R, et al. Central venous oxygen saturation in shock: a study in man. Anesthesiology 1972;36:472-8.
41. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Mad 2000;342:1301-8.
42. Granger CB, Califf RM, Young S, et al. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. J Am Coll Cardiol 1993;21:920-5.
43. Malmberg K, Norhammar A, Wedel H, et al. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation 1999;99:2626-32.
44. Wass CT, Lanier WL. Glucose modulation of ischemic brain injury: review and clinical recommendations. Mayo Clin Proc 1996;71:801-12.
45. Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995;26:57-65.
46. Scott JF, Robinson GM, French JM, et al. Glucose potassium insulin infusions in the treatment of acute stroke patients with mild to moderate hyperglycemia: the Glucose Insulin in Stroke Trial (GIST). Stroke 1999;30:793-9.
47. Michaud LJ, Rivara FP, Longstreth WT, Jr, et al. Elevated initial blood glucose levels and poor outcome following severe brain injuries in children. J Trauma 1991;31:1356-62.